288 related articles for article (PubMed ID: 23387409)
1. Compressed orally disintegrating tablets: excipients evolution and formulation strategies.
Al-khattawi A; Mohammed AR
Expert Opin Drug Deliv; 2013 May; 10(5):651-63. PubMed ID: 23387409
[TBL] [Abstract][Full Text] [Related]
2. Challenges and emerging solutions in the development of compressed orally disintegrating tablets.
Al-Khattawi A; Mohammed AR
Expert Opin Drug Discov; 2014 Oct; 9(10):1109-20. PubMed ID: 25045997
[TBL] [Abstract][Full Text] [Related]
3. The use of the SeDeM Diagram expert system to determine the suitability of diluents-disintegrants for direct compression and their use in formulation of ODT.
Aguilar-Díaz JE; García-Montoya E; Pérez-Lozano P; Suñe-Negre JM; Miñarro M; Ticó JR
Eur J Pharm Biopharm; 2009 Nov; 73(3):414-23. PubMed ID: 19602435
[TBL] [Abstract][Full Text] [Related]
4. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydrochloride.
Cantor SL; Khan MA; Gupta A
Drug Dev Ind Pharm; 2015; 41(7):1156-64. PubMed ID: 25000481
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of furosemide containing orally disintegrating tablets by direct compression.
Gulsun T; Ozturk N; Kaynak MS; Vural I; Sahin S
Pharmazie; 2017 Jul; 72(7):389-394. PubMed ID: 29441935
[TBL] [Abstract][Full Text] [Related]
6. A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study.
Teaima MH; Abdel-Haleem KM; Osama R; El-Nabarawi MA; Elnahas OS
Drug Des Devel Ther; 2021; 15():4229-4242. PubMed ID: 34675486
[TBL] [Abstract][Full Text] [Related]
7. Formulation and Quality Control of Orally Disintegrating Tablets (ODTs): Recent Advances and Perspectives.
Ghourichay MP; Kiaie SH; Nokhodchi A; Javadzadeh Y
Biomed Res Int; 2021; 2021():6618934. PubMed ID: 34977245
[TBL] [Abstract][Full Text] [Related]
8. Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and Physicomechanical Characterization.
Agiba AM; Abdel-Hamid S; Nasr M; Geneidi AS
Curr Drug Deliv; 2018 Feb; 15(2):267-277. PubMed ID: 28322163
[TBL] [Abstract][Full Text] [Related]
9. Investigating the Impact of Co-processed Excipients on the Formulation of Bromhexine Hydrochloride Orally Disintegrating Tablets (ODTs).
Woyna-Orlewicz K; Brniak W; Tatara W; Strzebońska M; Haznar-Garbacz D; Szafraniec-Szczęsny J; Antosik-Rogóż A; Wojteczko K; Strózik M; Kurek M; Jachowicz R; Mendyk A
Pharm Res; 2023 Dec; 40(12):2947-2962. PubMed ID: 37726407
[TBL] [Abstract][Full Text] [Related]
10. Microparticle surface layering through dry coating: impact of moisture content and process parameters on the properties of orally disintegrating tablets.
Alyami H; Koner J; Dahmash EZ; Bowen J; Terry D; Mohammed AR
J Pharm Pharmacol; 2017 Jul; 69(7):807-822. PubMed ID: 27696423
[TBL] [Abstract][Full Text] [Related]
11. New advances in the characterization of lyophilised orally disintegrating tablets.
Vanbillemont B; Everaert H; De Beer T
Int J Pharm; 2020 Apr; 579():119153. PubMed ID: 32084575
[TBL] [Abstract][Full Text] [Related]
12. Why is mannitol becoming more and more popular as a pharmaceutical excipient in solid dosage forms?
Ohrem HL; Schornick E; Kalivoda A; Ognibene R
Pharm Dev Technol; 2014 May; 19(3):257-62. PubMed ID: 23528124
[TBL] [Abstract][Full Text] [Related]
13. Predicting orally disintegrating tablets formulations of ibuprophen tablets: an application of the new SeDeM-ODT expert system.
Aguilar-Díaz JE; García-Montoya E; Suñe-Negre JM; Pérez-Lozano P; Miñarro M; Ticó JR
Eur J Pharm Biopharm; 2012 Apr; 80(3):638-48. PubMed ID: 22245156
[TBL] [Abstract][Full Text] [Related]
14. Coated dextrin microcapsules of amlodipine incorporable into orally disintegrating tablets for geriatric patients.
Jang DJ; Bae SK; Oh E
Biomed Pharmacother; 2014 Oct; 68(8):1117-24. PubMed ID: 25458788
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel direct compressible co-processed excipient and its application for formulation of Mirtazapine orally disintegrating tablets.
Loke YH; Chew YL; Janakiraman AK; Lee SK; Uddin ABMH; Goh CF; Kee PE; Ng HS; Ming LC; Liew KB
Drug Dev Ind Pharm; 2024 Jan; 50(1):36-44. PubMed ID: 38149637
[TBL] [Abstract][Full Text] [Related]
16. New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook.
Elwerfalli AM; Ghanchi Z; Rashid F; Alany RG; ElShaer A
Curr Drug Deliv; 2015; 12(6):652-67. PubMed ID: 25760951
[TBL] [Abstract][Full Text] [Related]
17. Systematic screening of compressed ODT excipients: cellulosic versus non-cellulosic.
Al-Khattawi A; Iyire A; Dennison T; Dahmash E; Bailey CJ; Smith J; Rue P; Mohammed AR
Curr Drug Deliv; 2014; 11(4):486-500. PubMed ID: 24655059
[TBL] [Abstract][Full Text] [Related]
18. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
19. Orally disintegrating mini-tablets (ODMTs)--a novel solid oral dosage form for paediatric use.
Stoltenberg I; Breitkreutz J
Eur J Pharm Biopharm; 2011 Aug; 78(3):462-9. PubMed ID: 21324357
[TBL] [Abstract][Full Text] [Related]
20. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
Mostafa HF; Ibrahim MA; Sakr A
Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
